eligibility_summary
Eligible: recurrent EOC, fallopian tube, or primary peritoneal cancer, prior bevacizumab (and PARP if BRCA+), adequate organ function, agrees to intraperitoneal catheter and biopsy if feasible, consent to 15-year follow-up. Exclude: pregnancy (neg test/contraception required), systemic immunosuppression/active autoimmune disease, severe asthma, uncontrolled infection, recent therapy/live vaccine, allergy to albumin/DMSO, prior enoblituzumab, CNS disease, HIV or active HBV/HCV, other risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I trial of intraperitoneal FT536, an allogeneic iPSC‑derived CAR NK-cell therapy engineered with: (1) CD38 knockout, (2) a MICA/MICB-targeting CAR, (3) high‑affinity, non‑cleavable CD16 (FcγRIIIa) to boost ADCC, and (4) an IL‑15/IL‑15Rα fusion for NK survival/persistence. Dosed on Days 1, 4, 8 after lymphodepleting chemotherapy: fludarabine (purine analog) and cyclophosphamide (alkylator). Targets/pathways: tumor cells expressing MICA/B (stress ligands), NK cytotoxicity and ADCC via CD16, IL‑15 signaling for expansion/activation, CD38 KO reduces adenosine/NADase‑mediated suppression, lymphodepletion lowers host lymphocytes to aid adoptive transfer.